SS
NAGE

Sunbelt Securities’s Niagen Bioscience NAGE Stock Holding History

Sunbelt Securities’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2
Closed -$13 – 3114
2025
Q4 		$13 Sell
2
-25
-93% -$174 ﹤0.01% 2755
2025
Q3 		$252 Buy
+27
New +$273 ﹤0.01% 2377

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sunbelt Securities's NAGE Position: Q1 2026 in Review

Sunbelt Securities sold out of Niagen Bioscience (NAGE) in Q1 2026, closing a stake of 2 shares — an estimated $13 sold.

Sunbelt Securities first reported a position in NAGE in Q3 2025 and held it in 2 quarters. The position peaked at $252 in Q3 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • Sunbelt Securities reported no remaining Niagen Bioscience position as of Q1 2026 after selling out during the quarter.
  • Sunbelt Securities sold 2 Niagen Bioscience shares in Q1 2026, an estimated $13.
  • Sunbelt Securities first reported a position in Niagen Bioscience in Q3 2025 and held it in 2 quarters.
  • Sunbelt Securities's Niagen Bioscience position peaked at $252 in Q3 2025.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.